Nuvalent to present pivotal lung cancer drug data at 2026 ASCO meeting in Chicago

Nuvalent, a clinical-stage biopharmaceutical company, will present pivotal Phase 1/2 trial data for neladalkib, an ALK-selective inhibitor for advanced ALK-positive non-small cell lung cancer (NSCLC), and preliminary data for zidesamtinib, a ROS1-selective inhibitor for advanced ROS1-positive solid tumors outside NSCLC, at the 2026 ASCO Annual Meeting in Chicago. Neladalkib targets tumors resistant to prior ALK inhibitors and penetrates the brain to treat metastases, while zidesamtinib is designed to overcome resistance in ROS1-positive tumors and also penetrates the brain. These presentations highlight Nuvalent's progress in developing targeted therapies for lung cancer, with neladalkib having FDA breakthrough therapy designation and zidesamtinib's NDA submission accepted with a target FDA decision date in September 2026.